论文部分内容阅读
目的 :研究特尔立 (GM -CSF)治疗急性白血病化疗后粒细胞减少的疗效。方法 :5 6例急性白血病患者随机分成特尔立治疗组和对照组。治疗组化疗结束后 72h给予特尔立 5 μg/Kg .d皮下注射 ,连续应用 5～ 14天 (或NAC≥ 1× 10 9/L时停用 )。对照组不加任何刺激造血药物。结果 :2 8例应用特尔立治疗的急性白血病患者NAC恢复到 0 5× 10 9/L和 1 0×10 9/L的时间分别为 7 2和 11 6天 ,较对照组分别缩短 4天和 7天 ;3～ 5级感染发生率和致死性感染发生率均较对照组降低 ;治疗过程中无明显不良反应发生。结论 :特尔立对急性白血病诱导化疗后白细胞减少有促进恢复作用 ,且能降低 3～ 5级感染率和致死性感染发生率 ;临床应用耐受性良好
Objective: To investigate the efficacy of telomere-reducing (GM-CSF) in the treatment of acute leukemia after chemotherapy. Methods: Fifty-six patients with acute leukemia were randomly divided into treatment and control groups. The treatment group was given subcutaneous injection of 5 μg/Kg.d subcutaneous injection 72 h after the end of chemotherapy, continuous application of 5 ~ 14 days (or NAC ≥ 1 × 10 9/L when disabled). The control group did not add any hematopoietic drugs. RESULTS: The time to recovery of NAC from 28 patients with acute leukemia treated with Telstar was 0 2 × 10 9 /L and 1 0 × 10 9 /L, respectively, 7 2 and 11 6 days, which was 4 days shorter than that of the control group. And 7 days; 3 to 5 infection incidence and fatal infection rate were lower than the control group; no significant adverse reactions occurred during treatment. Conclusion :Telli can promote the recovery of leukopenia after induction chemotherapy of acute leukemia, and can reduce the infection rate of 3 to 5 grades and the incidence of fatal infections; clinical application is well tolerated